Tag: Edwards Lifesciences

Edwards Lifesciences To Webcast Annual Meeting Of Stockholders

IRVINE, Calif., May 14, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, will host its Annual Meeting of Stockholders on Thursday, May 17, 2018 beginning at 10:00 a.m. PT (1:00 pm ET) at its corporate headquarters in Irvine, California. A live webcast of the […]

Edwards Lifesciences Reports First Quarter Results

IRVINE, Calif., April 24, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended March 31, 2018. First Quarter and Recent Highlights: Sales were $895 million, or $938 million on an adjusted basis Global THVT sales […]

Boston Scientific Prevails In European Patent Dispute With Edwards Lifesciences

MARLBOROUGH, Mass., April 16, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced that it, along with several other opponents, successfully opposed Edwards Lifesciences Corporation’s European patent EP 2,399,550 (‘550) in the European Patent Office (EPO), resulting in a revocation of the patent. The ‘550 patent was the only Edwards patent that […]

Edwards Lifesciences To Host Earnings Conference Call On April 24, 2018

IRVINE, Calif., April 10, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans to announce its operating results for the quarter ended March 31, 2018 after the market closes on Tuesday, April 24, 2018, and will host a conference call at 5:00 p.m. […]

Edwards Prevails In U.S. Patent Office Review That Finds Boston Scientific Transcatheter Valve Patent Claims Invalid

WASHINGTON, March 23, 2018 — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the United States Patent and Trademark Office (USPTO) decided in Edwards’ favor in an Inter Partes Review (IPR) of Boston Scientific’s U.S. transcatheter heart valve patent, […]

Edwards Completes Enrollment In PARTNER 3 Low-Risk CT Sub-Study, Updates Timeline For SAPIEN 3 Ultra System Launch In Europe

IRVINE, Calif., March 21, 2018 — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that enrollment is complete in the computed tomography (CT) imaging sub-study within the PARTNER 3 trial of the SAPIEN 3 valve. This randomized sub-study is examining […]

Edwards Lifesciences To Host Earnings Conference Call On February 1, 2018

IRVINE, Calif., Jan. 18, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans to announce its operating results for the quarter ended December 31, 2017 after the market closes on Thursday, February 1, 2018, and will host a conference call at 5:00 p.m. […]

Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference

NEW YORK, Dec. 7, 2017 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, will discuss the company’s strategy for longer-term growth, provide an update on its technology pipeline and share its financial guidance during its annual investor conference today […]

Edwards Lifescience Scoops Up Harpoon Medical for $100M

IRVINE, Calif., Dec. 6, 2017 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced the acquisition of Harpoon Medical, a privately held medical technology company pioneering beating-heart repair for degenerative mitral regurgitation (DMR). Edwards announced a structured upfront investment […]

Edwards Lifesciences (EW) Reports Second Quarter Results

IRVINE, Calif., July 26, 2017 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended June 30, 2017. Second Quarter and Recent Highlights: Sales grew 11 percent to $842 million; underlying1 sales increased 15 percent […]